iCAD's ProFound AI Can Predict 1-2 Year Risk for Breast Cancer and Reveal Insights for Heart Disease

Stock Information for iCad Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About iCad Inc.

Clinical AI Platforms Expand Globally Amid Regulatory and Market Tailwinds
iCAD Collaborates with Microsoft to provide access to its Mammography Solutions in Microsoft's Precision Imaging Network (PIN)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ICAD, WBA, RDW on Behalf of Shareholders
ICAD INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of iCAD, Inc. - ICAD
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ICAD, XAGE, DADA on Behalf of Shareholders
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of iCAD, Inc. - ICAD
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Longevity Health Holdings, Inc. (Nasdaq - XAGE), iCAD, Inc. (Nasdaq - ICAD), Beacon Roofing Supply, Inc. (Nasdaq - BECN), Dada Nexus Limited (Nasdaq - DADA)
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating iCAD, Inc. Buyout

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.